Navigation Links
Using a molecular switch to turn on cancer vaccines
Date:3/7/2011

The immune system is capable of recognizing tumor growth, and naturally mounts an anti-cancer defense. Dendritic cells (DCs) can take up tumor-derived molecules (antigens) and present them to T cells, and those "primed" T cells are then able to recognize and kill tumor cells. In recent years, researchers have attempted to capitalize upon these natural immune responses to develop new therapies- namely, by generating a pool of tumor antigen-pulsed DCs that might be used as vaccines to augment the T-cell responses of cancer patients. In clinical trials, these DC vaccines have had limited success, in part because the protocols to generate mature and active DCs in vitro are imperfect. Specifically, generation of mature DCs requires activation of Toll-Like receptors (TLRs), usually achieved by administration of lipopolysaccharide, which can cause toxic shock in humans and can promote apoptosis.

In this paper, David Spencer and colleagues, of Baylor University in Houston, Texas, addressed this problem by looking to the adaptor molecule downstream of the TLR, MyD88. They engineered a form of MyD88 that could induce downstream signaling in response to a drug, and expressed this inducible MyD88 (iMyD88) in DCs. Further, the researchers combined iMyD88 with a second pathway required for optimal activation of DCs- CD40 signaling- so that they could control both pathways with administration of a single drug. This combination improved DC-mediated tumor antigen-specific T cell responses in mouse cancer models and T cell responses to human tumor antigens. The researchers hope that this "switch" might be broadly applicable to the design of DC vaccines.


'/>"/>

Contact: Kathryn Claiborn
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Using amphetamines may increase risk of Parkinsons disease
2. A new high-resolution method for imaging below the skin using a liquid lens
3. Using Cell Phones Might Evoke Emotions, Study Suggests
4. Children in public housing play outdoors more
5. Using chlorhexidine gluconate baths to reduce hospital-acquired infections
6. UT Southwestern launches clinical trial for treatment of breast cancer using CyberKnife
7. Researchers identify the genotype of disorders causing cardiac sudden death syndrome
8. Using pharmacist-directed service improves quality of care for patients
9. Breathing easy: LSU biochemists offer first 3-D model of asthma-causing inflammation enzyme
10. Health-care systems not using best evidence in decision-making
11. Model predicts a drugs likelihood of causing birth defects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... , ... September 21, 2017 , ... With ProSlideshow Portrait ... and easy to do. Users can select from up to two layers of subject ... click of a mouse all within Final Cut Pro X. , With ...
(Date:9/21/2017)... Church, VA (PRWEB) , ... September 21, 2017 ... ... FDAnews Webinar**, Sept. 26, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... business. It’s easy to get things wrong, run afoul of The Quality System ...
(Date:9/21/2017)... ... September 21, 2017 , ... The American Addiction Treatment ... for professionals in the addiction treatment industry entitled: Special Investigations Unit (SIU) ... companies and state and federal governments are increasingly scrutinizing the addiction treatment industry ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
(Date:9/21/2017)... San Diego, Ca (PRWEB) , ... September 21, 2017 , ... ... and affordable services to its customers, and give back to the community. For over ... on of the most successful companies serving plumbing in San Diego. They ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
(Date:9/7/2017)... BOTHELL, Wash. , Sept. 7, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), announces that Mike Rice , President and ... Rodman & Renshaw 19 th ... 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
Breaking Medicine Technology: